Page last updated: 2024-09-03

imatinib mesylate and Bone Cancer

imatinib mesylate has been researched along with Bone Cancer in 59 studies

Research

Studies (59)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	38 (64.41)	29.6817
2010's	19 (32.20)	24.3611
2020's	2 (3.39)	2.80

Authors

Authors	Studies
Buchdunger, E; Germain, GS; Harwood, FC; Houghton, PJ; Schuetz, JD; Stewart, CF; Traxler, P	1
Jevtic, S; Lyons, SK; Ramirez, D; Safaric Tepes, P; Segovia, D; Sordella, R	1
Cheng, H; Lau, CC; Nan, X; Qiu, B; Sheng, J; Wang, J; Wong, STC; Yin, Z; Yustein, JT; Zhao, H	1
Hirano, H; Hirota, S; Iwamoto, H; Katayanagi, S; Katsumata, K; Kawachi, S; Makuuchi, Y; Osakabe, H; Sumi, T; Tsuchida, A; Yokoyama, T	1
Akgül Babacan, N; Akin Telli, T; Alan, O; Basoglu Tuylu, T; Dane, F; Ercelep, O; Hasanov, R; Kaya, S; Mutis, A; Tanrikulu Simsek, E; Yumuk, PF	1
Brich, S; Casale, A; Casali, PG; Cavalleri, A; Collini, P; Dinoi, G; Frezza, AM; Gronchi, A; Lo Vullo, S; Mariani, L; Messina, A; Morelli, D; Morosi, C; Palassini, E; Pilotti, S; Stacchiotti, S; Tamborini, E; Venturelli, E	1
Ali, CM; Chadli, D; Ibtissem, B; Leila, GE; Ramzi, N; Wejih, DM	1
Fujisawa, T; Matsumoto, Y; Nishizawa, A; Takata, M	1
Dourthe, LM; Heymann, S; Imperiale, A; Sauer, B; Schlund-Schoettel, E	1
Ebisui, C; Kinuta, M; Murakami, M; Murata, K; Nakagomi, N; Okada, K; Okamura, S; Tamai, M	1
Blay, JY; Cassier, P; Dufresne, A; Heudel, P; Pissaloux, D; Ray-Coquard, I; Wang, Q	1
Aubert, S; Chauffert, B; Lebellec, L; Penel, N; Ryckewaert, T; Zaïri, F	1
Ammendola, M; De Sarro, G; Gadaleta, CD; Leporini, C; Marech, I; Oakley, C; Ranieri, G; Russo, E; Sacco, R; Sammarco, G	1
Ando, T; Hosokawa, A; Kudo, T; Maeda, K; Miwa, S; Miyazaki, T; Nakajima, T; Nozawa, H; Sugiyama, T; Yamada, K	1
Hiraga, T; Nakamura, H	1
Blay, JY; Debiec-Rychter, M; Gelderblom, H; Guchelaar, HJ; Judson, I; Peng, B; van Erp, N; van Glabbeke, M; Van Oosterom, A; Verweij, J	1
Bakhshi, S; Das, P; Gupta, SD; Kalita, D; Radhakrishnan, S; Singh, S	1
Bovée, JV; Gelderblom, H; Hogendoorn, PC; Kroep, JR; van der Molen, AJ	1
Cesario, A; Cusumano, G; Lococo, F; Margaritora, S; Meacci, E	1
Campbell-Baird, C; Costa, L; Demers, L; Harvey, H; Kim, C; Lipton, A	1
Adibelli, Z; Alacacioğlu, A; Aykaş, A; Ozan, E; Oztekin, O; Postaci, H	1
Budd, GT; Chao, J; Chow, WA; Chu, P; Frankel, P; Garcia, D; Junqueira, M; Loera, S; Sato, J; Somlo, G	1
Ghose, A; Mohamed, I; Rafiq, E; Tariq, Z	1
Aglietta, M; Boglione, A; Casali, PG; Comandone, A; Ferraresi, V; Ferrari, S; Frustaci, S; Grignani, G; Palmerini, E; Stacchiotti, S	1
Mathew, P; Morita, S; Thall, PF; Wen, S	1
Acar, H; Aydemir, E; Bayrak, OF; Gulluoglu, S; Ozen, M; Sahin, F; Sevli, S; Yalvac, ME	1
Bertucci, F; Chetaille, B; Guiramand, J; Launay, SG; Medina, F; Moureau-Zabotto, L; Nazarian, S; Perrot, D	1
Alves, MT; Burnier, MN; de Toledo, SR; Di Cesare, S; Garcia, RJ; Miiji, LN; Odashiro, AN; Petrilli, AS	1
Boos, J; Hotfilder, M; Jürgens, H; Lanvers, C; Vormoor, J	1
Cohen, MH; Dagher, R; Griebel, DJ; Ibrahim, A; Martin, A; Pazdur, R; Scher, NS; Sokol, GH; Williams, GA	1
Bar-Eli, M; Doucet, M; Fidler, IJ; Lev, DC; Lewis, V; McGary, EC; Mills, L; Weber, K	1
Druker, BJ	1
Mackall, CL; Merchant, MS; Thiele, CJ; Woo, CW	1
Fan, D; Fidler, IJ; Karashima, T; Killion, JJ; Kim, SJ; Logothetis, C; Mathew, P; Shepherd, DL; Tsan, R; Uehara, H	1
Astolfi, A; Benini, S; Bertoni, F; Landuzzi, L; Lollini, PL; Manara, MC; Nanni, P; Nicoletti, G; Perdichizzi, S; Picci, P; Scotlandi, K; Serra, M; Strammiello, R	1
Albertini, V; Bonadiman, L; Pierotti, MA; Pilotti, S; Tamborini, E	1
Aburatani, H; Hanyu, A; Imamura, T; Iwadate, M; Kondo, M; Matsuyama, S; Mishima, HK; Miyazawa, K; Miyazono, K; Saitoh, M; Shimizu, K	1
Andreu, EJ; de Alava, E; Fernández-Luna, JL; Fontalba, A; Gaboli, M; González, I; Inogés, S; Martín-Algarra, S; Panizo, A; Pardo, J; Prósper, F; Sierrasesúmaga, L	1
Beer, TM; Garzotto, M; Tiffany, NM; Wersinger, EM	1
Fidler, IJ; Logothetis, CJ; Mathew, P	1
Brink, I; Dirnhofer, S; Hartmann, M; Jakob, A; Marx, A; Mikesch, K; Ströbel, P	1
Fan, D; Fidler, IJ; He, J; Killion, JJ; Kim, SJ; Langley, RR; Tsan, R; Uehara, H; Yazici, S	1
Bilgrami, S; Kapur, D; Smaradottir, A	1
Bucana, C; Fidler, IJ; Jones, D; Kim, SJ; Logothetis, C; Mathew, P; Perez, C; Thall, PF; Troncoso, P	1
Chuman, H	1
Altundag, K; Altundag, O; Gunduz, M; Morandi, P	1
Fidler, IJ; Kim, SJ; Lev, DC; Nam, DH; Onn, A; Price, JE; Stone, V; Yazici, S	1
Fan, D; Fidler, IJ; He, J; Kim, SJ; Langley, RR; Mathew, P; Uehara, H; Yazici, S	1
Campos, M; de Alava, E; Hernández, T; Mackintosh, C; Martín, DH; Martins, AS; Ordóñez, JL	1
Busby, JE; Do, KA; Fan, D; Fidler, IJ; He, J; Kim, SJ; Logothetis, C; Mathew, P; Maya, M; Nakamura, T; Uehara, H; Wang, X; Yazici, S	1
Fidler, IJ	1
Hirai, S; Ishikawa, A; Kakinoki, N; Kamoshida, T; Kishimoto, Y; Ochiai, T; Oka, Y; Ono, S; Shimokama, T; Teratani, T	1
Adamson, PC; Bernstein, ML; Blaney, SM; Bond, M; Krailo, M; Pappo, A; Schultz, KR	1
Araujo, ES; Bacchini, P; Bertoni, F; Do, I; Kalil, RK; Park, YK; Unni, KK	1
Bonvalot, S; Cesne, AL; Cioffi, A; Domont, J; Pechoux, CL; Vanel, D	1
Bubley, G; Derynck, MK; Lin, AM; Park, M; Rini, BI; Rosenberg, JE; Ryan, CJ; Small, EJ; Weinberg, V	1
Bucana, CD; Cohen, L; Fidler, IJ; Johnson, MM; Jones, DM; Kim, SJ; Logothetis, CJ; Mathew, P; Meluch, AA; Morris, MJ; Oh, WK; Pagliaro, LC; Smith, L; Tannir, NM; Thall, PF; Troncoso, P; Tu, SM; Wen, S	1
Antonescu, CR; Chen, W; Gorlick, R; Healey, JH; Huvos, AG; Kim, HS; Kubo, T; Meyers, PA; Piperdi, S; Rosenblum, J; Sowers, R	1
Fisher, GA; Levitt, L; Lin, AY; So, S; Tang, C	1

Reviews

9 review(s) available for imatinib mesylate and Bone Cancer

Article	Year
Chordoma: a case series and review of the literature. Journal of medical case reports, 2018, Aug-27, Volume: 12, Issue:1 Topics: Adult; Aged; Bone Neoplasms; Chordoma; Cranial Fossa, Posterior; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sacrum; Skull Base Neoplasms; Spinal Neoplasms; Sunitinib	2018
[Molecular biology of sarcoma and therapeutic choices]. Bulletin du cancer, 2015, Volume: 102, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzamides; Bone Neoplasms; Crizotinib; Denosumab; Dermatofibrosarcoma; Gastrointestinal Stromal Tumors; Gene Amplification; Gene Deletion; Giant Cell Tumor of Bone; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Phenylurea Compounds; Piperazines; Point Mutation; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sarcoma; Sarcoma, Ewing; Sunitinib; Synovitis, Pigmented Villonodular; Translocation, Genetic	2015
Molecular targeted therapies in advanced or metastatic chordoma patients: facts and hypotheses. Critical reviews in oncology/hematology, 2015, Volume: 95, Issue:1 Topics: Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Chordoma; ErbB Receptors; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptors, Platelet-Derived Growth Factor; Vascular Endothelial Growth Factor A	2015
Targeting mast cells in gastric cancer with special reference to bone metastases. World journal of gastroenterology, 2015, Oct-07, Volume: 21, Issue:37 Topics: Animals; Antigens, CD34; Benzamides; Benzamidines; Bone and Bones; Bone Neoplasms; Bone Resorption; Disease Progression; Gabexate; Guanidines; Humans; Imatinib Mesylate; Immune System; Mast Cells; Neovascularization, Pathologic; NF-kappa B; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Stomach Neoplasms; Thiazoles; Tryptases	2015
[Three cases of gastrointestinal stromal tumor (GIST) with bone metastasis]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2008, Volume: 105, Issue:6 Topics: Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Digestive System Surgical Procedures; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Male; Middle Aged; Piperazines; Pyrimidines; Rectum; Risk; Time Factors	2008
Extra-abdominal subcutaneous metastasis of a gastrointestinal stromal tumor: report of a case and a review of the literature. Journal of cutaneous pathology, 2009, Volume: 36, Issue:5 Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Carcinoma; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indoles; Liver Neoplasms; Piperazines; Pyrimidines; Pyrroles; Soft Tissue Neoplasms; Subcutaneous Fat; Sunitinib	2009
Efficacy of epidermal growth factor receptor targeting in advanced chordoma: case report and literature review. BMC cancer, 2011, Oct-04, Volume: 11 Topics: Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chordoma; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Male; Molecular Targeted Therapy; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Treatment Outcome	2011
Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Seminars in oncology, 2004, Volume: 31, Issue:2 Suppl 6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Delivery Systems; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Taxoids	2004
[Current strategy of chemotherapy for reflactory bone and soft tissue sarcomas]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Imatinib Mesylate; Lung Neoplasms; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids	2004

Trials

11 trial(s) available for imatinib mesylate and Bone Cancer

Article	Year
Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study. Cancer, 2018, 10-15, Volume: 124, Issue:20 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chordoma; Disease Progression; Everolimus; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Sarcoma; Skull Base Neoplasms; Spinal Neoplasms; Survival Analysis	2018
Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases. American journal of clinical oncology, 2010, Volume: 33, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imatinib Mesylate; Imidazoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Piperazines; Prognosis; Prostatic Neoplasms; Pyrimidines; Sarcoma; Survival Rate; Treatment Outcome; Zoledronic Acid	2010
Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer research, 2010, Volume: 30, Issue:2 Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Neoplasms; Carcinoma, Small Cell; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Neuroectodermal Tumors, Primitive; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sarcoma, Ewing; Survival Rate; Treatment Outcome	2010
A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study. Cancer, 2011, Feb-15, Volume: 117, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chondrosarcoma; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Recurrence; Treatment Outcome	2011
Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2011, Volume: 31, Issue:7 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Pharmacological; Bone Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Imatinib Mesylate; Male; Piperazines; Placenta Growth Factor; Pregnancy Proteins; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Pyrimidines; Taxoids	2011
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology, 2004, Volume: 63, Issue:5 Topics: Aged; Antineoplastic Agents; Benzamides; Bone Diseases; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Drug Therapy, Combination; Humans; Imatinib Mesylate; Imidazoles; Male; Middle Aged; Pain; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Treatment Failure; Zoledronic Acid	2004
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Aug-15, Volume: 22, Issue:16 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Taxoids	2004
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatric blood & cancer, 2008, Volume: 50, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Neoplasms; Carcinoma, Small Cell; Child; Child, Preschool; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Osteosarcoma; Piperazines; Pyrimidines; Sarcoma, Ewing; Sarcoma, Synovial	2008
A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clinical genitourinary cancer, 2007, Volume: 5, Issue:5 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Estramustine; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Survival Rate; Taxoids; Treatment Outcome	2007
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Oct-01, Volume: 13, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Castration; Cohort Studies; Disease-Free Survival; Docetaxel; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Placebos; Prostatic Neoplasms; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Taxoids	2007
Phase II study of imatinib in unresectable hepatocellular carcinoma. American journal of clinical oncology, 2008, Volume: 31, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Heart Neoplasms; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Treatment Outcome	2008

Other Studies

39 other study(ies) available for imatinib mesylate and Bone Cancer

Article	Year
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer research, 2004, Apr-01, Volume: 64, Issue:7 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Irinotecan; Neoplasm Proteins; Osteosarcoma; Piperazines; Pyrimidines; Topotecan	2004
Patient-derived xenografts and in vitro model show rationale for imatinib mesylate repurposing in HEY1-NCoA2-driven mesenchymal chondrosarcoma. Laboratory investigation; a journal of technical methods and pathology, 2022, Volume: 102, Issue:9 Topics: Basic Helix-Loop-Helix Transcription Factors; Bone Neoplasms; Carcinogenesis; Cell Cycle Proteins; Chondrosarcoma, Mesenchymal; Drug Repositioning; Heterografts; Humans; Imatinib Mesylate; Nuclear Receptor Coactivator 2	2022
Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways. Cancer letters, 2020, 01-28, Volume: 469 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Cycle Checkpoints; Cell Hypoxia; Cell Line, Tumor; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Imatinib Mesylate; Male; Metformin; Mice; Oncogene Proteins, Fusion; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Progression-Free Survival; Proto-Oncogene Protein c-fli-1; Proto-Oncogene Proteins c-akt; RNA-Binding Protein EWS; RNA-Seq; Sarcoma, Ewing; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2020
Long-Term Survival After Multidisciplinary Treatment Including Surgery for Metachronous Metastases of Small Intestinal Gastrointestinal Stromal Tumors after Curative Resection: A Case Report. The American journal of case reports, 2019, Dec-26, Volume: 20 Topics: Bone Neoplasms; Combined Modality Therapy; Fatal Outcome; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leiomyosarcoma; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Sunitinib	2019
Rectal stromal tumor with an exceptional liver and bone metastatic locations. The Pan African medical journal, 2019, Volume: 32 Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Rectal Neoplasms; Tomography, X-Ray Computed	2019
[A case of liver and bone metastases after complete resection of gastric GIST effectively treated with radiotherapy and imatinib mesylate]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2013, Volume: 110, Issue:7 Topics: Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Combined Modality Therapy; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Piperazines; Pyrimidines	2013
[A rare case of bone metastasis from gastro-intestinal stromal tumour: place of radiotherapy]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2014, Volume: 18, Issue:1 Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Femoral Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Humerus; Imatinib Mesylate; Ischium; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Osteolysis; Pain Management; Peritoneal Neoplasms; Piperazines; Pubic Bone; Pyrimidines; Stomach Neoplasms	2014
[A case of liver and bone metastasis from gastrointestinal stromal tumor treated using imatinib]. Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:1 Topics: Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Piperazines; Positron-Emission Tomography; Pyrimidines; Recurrence; Stomach Neoplasms	2014
Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals. International journal of cancer, 2009, Jan-01, Volume: 124, Issue:1 Topics: Animals; Antineoplastic Agents; Benzamides; Bone and Bones; Bone Neoplasms; Cell Line; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice; Mice, Nude; Neoplasm Metastasis; Osteoclasts; Piperazines; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor	2009
Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Dec-15, Volume: 14, Issue:24 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Neoplasms; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Sarcoma; Smoking; Soft Tissue Neoplasms	2008
Presentation of childhood CML mimicking bone sarcoma. Pediatric blood & cancer, 2009, Volume: 52, Issue:7 Topics: Adolescent; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Neoplasms; Diagnosis, Differential; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Osteosarcoma; Piperazines; Pyrimidines	2009
Pulmonary metastases from parachordoma. The Annals of thoracic surgery, 2009, Volume: 88, Issue:2 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Neoplasms; Chordoma; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Lung Neoplasms; Piperazines; Pyrimidines; Solitary Pulmonary Nodule; Tomography, X-Ray Computed	2009
Esophageal gastrointestinal stromal tumor with pulmonary and bone metastases. Diagnostic and interventional radiology (Ankara, Turkey), 2010, Volume: 16, Issue:3 Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Esophageal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Pyrimidines; Tomography, X-Ray Computed	2010
Gastrointestinal stromal tumor with primary resistance to imatinib and extensive bone metastases. American journal of therapeutics, 2011, Volume: 18, Issue:5 Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2011
The effects of chemotherapeutic agents on differentiated chordoma cells. Journal of neurosurgery. Spine, 2011, Volume: 15, Issue:6 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Chordoma; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Imatinib Mesylate; Methotrexate; Piperazines; Pyrimidines; Vidarabine; Vincristine	2011
C-kit expression in human osteosarcoma and in vitro assays. International journal of clinical and experimental pathology, 2011, Volume: 4, Issue:8 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Immunohistochemistry; In Vitro Techniques; Kaplan-Meier Estimate; Male; Osteosarcoma; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies	2011
c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:2 Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Neoplasm Proteins; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Ewing; Signal Transduction; Tumor Cells, Cultured	2002
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. The oncologist, 2002, Volume: 7, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Neoplasms; Cystitis; Diphosphonates; Drug Approval; Gastrointestinal Neoplasms; Hematuria; Hemorrhage; Humans; Ifosfamide; Imatinib Mesylate; Imidazoles; Mesna; Multiple Myeloma; Orphan Drug Production; Piperazines; Protective Agents; Pyrimidines; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Zoledronic Acid	2002
Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:11 Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Bone Neoplasms; Cell Division; Cell Line, Transformed; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; In Situ Nick-End Labeling; Mice; Neoplasm Transplantation; Osteosarcoma; Paclitaxel; Phosphorylation; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Tibia; Time Factors; Tumor Cells, Cultured	2002
Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work? Journal of the National Cancer Institute, 2002, Nov-20, Volume: 94, Issue:22 Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma, Ewing; Treatment Outcome; Tumor Cells, Cultured	2002
Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity. Journal of the National Cancer Institute, 2002, Nov-20, Volume: 94, Issue:22 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone Neoplasms; Disease Models, Animal; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoblotting; Inhibitory Concentration 50; Phosphorylation; Piperazines; Precipitin Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma, Ewing; Stem Cell Factor; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured	2002
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases. Journal of the National Cancer Institute, 2003, Mar-19, Volume: 95, Issue:6 Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Neoplasms; Cell Division; Disease Models, Animal; Enzyme Inhibitors; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Microcirculation; Neoplasms, Experimental; Paclitaxel; Phosphorylation; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Radiographic Image Enhancement; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Tumor Cells, Cultured	2003
C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-15, Volume: 21, Issue:10 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Cell Division; Cell Movement; Child; Doxorubicin; Drug Synergism; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma, Ewing; Survival Analysis; Tumor Cells, Cultured	2003
Re: Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. Journal of the National Cancer Institute, 2003, Jul-16, Volume: 95, Issue:14 Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; In Vitro Techniques; Oncogene Proteins; Phosphorylation; Piperazines; Precipitin Tests; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Ewing	2003
SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer research, 2003, Nov-15, Volume: 63, Issue:22 Topics: Activin Receptors, Type I; Activin Receptors, Type II; Animals; Antineoplastic Agents; Benzamides; Bone Neoplasms; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dioxoles; Drug Interactions; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice; NIH 3T3 Cells; Oligonucleotide Array Sequence Analysis; Osteosarcoma; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-myc; Pyrimidines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta; Up-Regulation	2003
Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-15, Volume: 10, Issue:2 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Blotting, Western; Bone Neoplasms; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Enzyme Inhibitors; Flow Cytometry; Humans; Imatinib Mesylate; Immunohistochemistry; Indicators and Reagents; Inhibitory Concentration 50; Ligands; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Piperazines; Precipitin Tests; Propidium; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sarcoma, Ewing; Signal Transduction; Stem Cell Factor; Vincristine	2004
Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. The New England journal of medicine, 2004, Jun-17, Volume: 350, Issue:25 Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Disease Progression; Fatal Outcome; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Sequence Analysis, DNA; Sequence Deletion; Thymoma; Thymus Neoplasms	2004
Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer research, 2004, Jun-15, Volume: 64, Issue:12 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Neoplasms; Cell Division; Enzyme Inhibitors; ErbB Receptors; Humans; Imatinib Mesylate; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Prostatic Neoplasms; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Substrate Specificity; Xenograft Model Antitumor Assays	2004
Unusual extramedullary relapse of CML. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:8 Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Genes, abl; Humans; Ilium; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Tomography, X-Ray Computed	2004
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. Urology, 2005, Volume: 65, Issue:1 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Diphosphonates; Humans; Imatinib Mesylate; Imidazoles; Male; Neoplasm Proteins; Palliative Care; Piperazines; Prostatic Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Treatment Failure; Zoledronic Acid	2005
Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jan-01, Volume: 11, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Female; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Microcirculation; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Platelet-Derived Growth Factor; Pyrimidines; Radiography; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Time Factors	2005
Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer research, 2005, May-01, Volume: 65, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imatinib Mesylate; Imidazoles; Immunohistochemistry; Male; Mice; Mice, Nude; Osteoclasts; Paclitaxel; Piperazines; Prostatic Neoplasms; Pyrimidines; Zoledronic Acid	2005
Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jun-01, Volume: 12, Issue:11 Pt 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Screening Assays, Antitumor; G1 Phase; Humans; Imatinib Mesylate; Phosphorylation; Piperazines; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Sarcoma, Ewing; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Vincristine	2006
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. Journal of the National Cancer Institute, 2006, Jun-07, Volume: 98, Issue:11 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelial Cells; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Lymphatic Metastasis; Male; Mice; Mice, Nude; Microcirculation; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Random Allocation; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Tibia; Tumor Cells, Cultured	2006
Antivascular therapy of cancer metastasis. Journal of surgical oncology, 2006, Sep-01, Volume: 94, Issue:3 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Growth Substances; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Pyrimidines; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor	2006
[A case of gastrointestinal stromal tumor with liver and bone metastases effectively treated with radiofrequency ablation and imatinib mesylate]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2006, Volume: 103, Issue:11 Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Catheter Ablation; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestine, Small; Liver Neoplasms; Male; Middle Aged; Piperazines; Pyrimidines	2006
Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas. Pathology, research and practice, 2007, Volume: 203, Issue:3 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Neoplasms; Child; Child, Preschool; DNA Mutational Analysis; Exons; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Infant; Korea; Male; Middle Aged; Mutation; Paraffin Embedding; Patient Selection; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Sarcoma, Ewing	2007
Imatimid-induced bone marrow necrosis detected on MRI examination and mimicking bone metastases. Skeletal radiology, 2007, Volume: 36, Issue:9 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Diseases; Bone Neoplasms; Diagnosis, Differential; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Necrosis; Pelvic Bones; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction	2007
Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer, 2008, May-15, Volume: 112, Issue:10 Topics: Adolescent; Adult; Aged; Becaplermin; Benzamides; Biomarkers, Tumor; Blotting, Western; Bone Neoplasms; Cell Survival; Child; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Immunoprecipitation; Male; Middle Aged; Mitogen-Activated Protein Kinases; Osteosarcoma; Phosphorylation; Piperazines; Platelet-Derived Growth Factor; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured	2008